メインコンテンツに移動
News
-
- November 01, 2023 Company
- Ono Pharmaceutical Co., Ltd. Announced 2023 2Q Financial Results
-
- September 27, 2023 Licensing
- Ono Pharmaceutical Co., Ltd. Enters into a Drug Discovery Collaboration Agreement with Adimab to Discover Novel Antibody Drugs in the Oncology Field
-
- August 31, 2023 Licensing
- Ono Pharmaceutical Co., Ltd. Enters into a Drug Discovery Collaboration Agreement with Twist Bioscience to Discover Novel Antibodies for Autoimmune Diseases
-
- July 31, 2023 Company
- Ono Pharmaceutical Co., Ltd. Announced 2023 1Q Financial Results
-
- May 10, 2023 Company
- Ono Pharmaceutical Co., Ltd. Announced 2022 Full Year Financial Results
-
- April 18, 2023 Company
- ONO PHARMA USA Announces 2023 Golden Ticket Competition in Partnership with LabCentral and MBC BioLabs
-
- March 22, 2023 R & D
- ONO PHARMA USA’s Tirabrutinib Receives Orphan Drug Designation from the FDA for the Treatment of Primary Central Nervous System Lymphoma
-
- February 24, 2023 Licensing
- Ono Pharmaceutical Co., Ltd. Enters into a Collaboration and Option Agreement with Cue Biopharma for CUE-401, a Bispecific Protein
-
- February 17, 2023 Company
- Ono Pharmaceutical Co., Ltd. Supports for Relief Efforts in the Earthquake in Turkey and Syria
-
- January 31, 2023 Company
- Ono Pharmaceutical Co., Ltd. Announced 2022 3Q Financial Results
-
- January 25, 2023 Licensing
- Ono Pharmaceutical Co., Ltd. Acquires Multiple Research-Stage Oncology Programs from KSQ Therapeutics
-
- December 27, 2022 Sustainability
- Ono Pharmaceutical Co., Ltd. Selected for the DJSI World Index and DJSI Asia Pacific Index for Three Straight Years
-
- December 27, 2022 Sustainability
- Ono Pharmaceutical Co., Ltd. Selected as a Highest Rating A-List Company for Both “Climate Change” and “Water Security” in CDP 2022
-
- December 06, 2022 Licensing
- Ono Pharmaceutical Co., Ltd. and Equillium Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
-
- October 31, 2022 Company
- Ono Pharmaceutical Co., Ltd. Announced 2022 2Q Financial Results
-
- August 31, 2022 Company
- ONO PHARMA USA continues to expand its organization for enhancement of R&D activities and future commercialization opportunities in the U.S.
-
- August 29, 2022 R & D
- ONO PHARMA USA Initiated Phase 1 Study of ONO-7018, a MALT1 Inhibitor,in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia in the U.S.
-
- August 01, 2022 Company
- Ono Pharmaceutical Co., Ltd. Announced 2022 1Q Financial Results
-
- May 11, 2022 Company
- Ono Pharmaceutical Co., Ltd. Announced 2021 Full Year Financial Results
-
- January 31, 2022 Company
- Ono Pharmaceutical Co., Ltd. Announced 2021 3Q Financial Results
-
- December 15, 2021 Sustainability
- Ono Pharmaceutical Co., Ltd. Selected as a Highest Rating A-List Company for Both “Climate Change” and “Water Security” in CDP 2021
-
- November 01, 2021 Company
- Ono Pharmaceutical Co., Ltd. Announced 2021 2Q Financial Results
-
- October 19, 2021 R & D
- ONO PHARMA USA Announces Initiation of Phase 1 Study of ONO-4685, an Anti-PD-1/CD3 Bispecific Antibody, in Patients with Relapsed or Refractory T-cell Lymphoma in the U.S (108KB)
-
- September 28, 2021 Company
- ONO PHARMA USA Appoints David Trexler as Chief Commercial Officer to Strengthen U.S. Leadership (112KB)
-
- July 30, 2021 Company
- Ono Pharmaceutical Co., Ltd. Announced 2021 1Q Financial Results
-
- July 19, 2021 R & D
- ONO PHARMA USA Announces the Initiation of Phase 2 Study of Tirabrutinib, a BTK Inhibitor, in Patients with Primary Central Nervous System Lymphoma (110KB)
-
- May 11, 2021 Company
- Ono Pharmaceutical Co., Ltd. Announced 2020 Full Year Financial Results
-
- April 27, 2021 Company
- Announcement of New Office Establishment (318KB)
-
- March 26, 2021 Company
- Ono Pharmaceutical Co., Ltd. Joins the University of California Drug Discovery Consortium
-
- March 17, 2021 Company
- Ono Pharmaceutical Co., Ltd. Entered Sponsorship Agreements with LabCentral and MBC BioLabs
-
- February 01, 2021 Company
- Ono Pharmaceutical Co., Ltd. Announces 2020 3Q Financial Results
-
- December 25, 2020 Company
- ONO PHARMA USA launches a new website. (316KB)